Explaining all without causing unnecessary harm : is there scope for positively framing medical risk information? by Webster, R.K. et al.
This is a repository copy of Explaining all without causing unnecessary harm : is there 
scope for positively framing medical risk information?.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/159129/
Version: Accepted Version
Article:
Webster, R.K. orcid.org/0000-0002-5136-1098, Weinman, J. and Rubin, G.J. (2019) 
Explaining all without causing unnecessary harm : is there scope for positively framing 
medical risk information? Patient Education and Counseling, 102 (3). pp. 602-603. ISSN 
0738-3991 
https://doi.org/10.1016/j.pec.2018.09.014
Article available under the terms of the CC-BY-NC-ND licence 
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
 
 
 
 
 
 
 
Explaining all without causing unnecessary harm: Is there scope for positively framing 
medical risk information? 
 
 
Webster, R. K
1,3
., Weinman, J
2,3
., & Rubin, G. J
1,3 
 
 
1. Department of Psychological Medicine, Kings College London, London, UK 
 
2. School of Cancer and Pharmaceutical Sciences, Kings College London, London, UK 
 
3. NIHR Health Protection Research Unit in Emergency Preparedness and Response, Kings 
College London, London, UK 
 
 
 
Corresponding author at Rebecca Webster; Weston Education Centre, 10 Cutcombe Road, 
London, SE5 9RJ, UK; Rebecca.webster@kcl.ac.uk; 020 7848 5686 
 
 
 
 
2 
 
Declaration of interest 
We declare no conflicts of interest. 
 
Contributor statement 
RW wrote the first draft of the article. JW and GJR contributed to the subsequent revisions. 
All authors approved the final version. 
 
Funding 
Rebecca Webster, John Weinman and James Rubin are affiliated to the National Institute for 
Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness 
and Response at Kings College London in partnership with Public Health England (PHE), in 
collaboration with the University of East Anglia and Newcastle University. The views 
expressed are those of the authors and not necessarily those of the NHS, the NIHR, the 
Department of Health or Public Health England. The funders had no input in the writing of 
and the decision to submit this article.  
 
 
 
 
 
 
3 
 
Highlights 
x Clinicians in the UK are now legally required to tell patients about every risk involved 
in any prescribed medical treatment 
x Informing patients of all risks such as side-effects however, may unintentionally 
increase the incidence of the very side-effects that are warned about 
x Positively framing risk information could be a solution to this dilemma, and we argue 
this should also be considered by other countries 
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Abstract 
Clinicians in the United Kingdom are now legally obliged to tell patients about every risk 
involved in prescribed medical treatments. Although important for informed consent, warning 
patients of risks such as side-effects can increase the incidence of these very side-effects, 
through the nocebo effect. Positively framing risk information could be a potential solution to 
this dilemma, and preliminary data has shown it is effective in healthy volunteers receiving a 
sham drug. Future research is needed to test its effectiveness in a clinical population. 
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In 2015 the UK Supreme Court passed a challenging legal judgement [1] requiring clinicians 
to tell patients about every risk involved in any prescribed medical treatment, and making 
clear that clinicians do not have the power to decide what information a patient should be 
given. This is an important judgement from a communication point of view, as explaining the 
risks involved in medical treatments is necessary in order for patients to make informed 
decisions about whether to adhere to a certain medicine regimen or agree to a medical 
procedure. The ruling was based upon the case of birthing complications arising from a 
patients medical condition which was not initially disclosed. The risk information however 
for any prescribed medical treatment is wide-ranging and complications only make up a part 
of this. Another important part which is particularly essential for prescribed medications, 
concerns side-effects. This poses a dilemma. Although provision of information about side-
effects is a necessary component to lead to informed consent, at the same time it may 
unintentionally increase the incidence of the very side-effects that are warned about, through 
a psychological phenomenon known as the nocebo effect [2]. 
 
Nocebo effects are defined as the experience of symptoms in response to a sham exposure [3] 
and are thought to explain many of the side-effects that patients experience and attribute to 
their medications [2]. Nocebo effects can occur to any medication whether available over-
the-counter or prescribed for a specific medical condition. They tend to manifest as non-
specific symptoms similar to those that people experience in everyday life, e.g. headache, 
nausea, fatigue, and which are then attributed to the medication [4]. They primarily occur 
through negative expectations, if patients expect to get side-effects from a sham  noxious 
exposure they will have an increased chance of experiencing them [5]. These expectations 
can be generated from a variety of sources such as media reports, conversations with friends 
and family, and warnings of side-effects in doctor-patient consultations or patient information 
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leaflets (PILs). Most recently, for example, media attention has highlighted the high rates of 
statin-associated side-effects such as muscle pain reported in clinical practice, despite the low 
rates observed in clinical trials [6]. This discrepancy could be nocebo-related, driven by 
warnings about adverse effects communicated by clinicians and by media reports, elevating 
anxiety, expectation and hence experience of side-effects among patients [7].   
 
Side-effects can be a worrisome burden to patients, decreasing their well-being and affecting 
medication adherence and the resulting therapeutic benefit, as has been shown in 
antiretroviral therapy for human immunodeficiency virus [8]. They are also an important 
determinant of non-adherence for all types of medication [9]. It has been estimated that over 
200,000 patients stopped taking their statin medication in the 6 months after adverse media 
coverage about statin side-effects, and as a result we can expect more than 2,000 additional 
cardiovascular events across the UK over the next decade [10]. As such,  not only do side-
effects affect patients but they also have ramifications for healthcare services, costing the 
NHS billions in additional healthcare costs [11] as the result of lowered adherence.  
 
One way to reduce side-effects is to reduce nocebo effects. The current literature discusses 
withholding side-effect information in an effort to reduce expectations and therefore nocebo 
induced side-effects [12].Even though this process might reduce side-effects, it does not 
adhere to the ruling of the UK Supreme Court. One potential resolution to this apparent 
impasse in the UK is the use of positive framing. The framing effect represents a type of 
cognitive bias, in which people react to a described probability in different ways depending 
on how it is presented; e.g. as a loss (negative) or as a gain (positive) [13]. This use of 
message framing has been extensively studied in a number of decisional domains and has 
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been shown to influence consumer choice [14], preferences for therapies [15], and 
engagement in health behaviours [16]. 
 
Currently medication side-effect information must be communicated in PILs, listing side-
effects in terms of how common they are, with the associated number of people who will be 
affected (e.g. Common, 1 in 10 people will be affected). Reframing side-effects positively 
would involve presenting side-effect risk information in terms of the number of people who 
will not be affected (e.g. Uncommon, 9 in 10 people will not be affected). Positive framing 
is an example of libertarian paternalism [17], which often uses nudge techniques to guide 
peoples choices in a way that will improve outcomes, without withholding any information, 
and therefore without infringing informed consent or patient autonomy. In a randomised 
controlled trial of 203 healthy volunteers we found that positively framing side-effects in 
PILs compared to current practice significantly reduced the proportion of participants 
experiencing symptoms and attributing them to a sham drug (39.2% in the positively framed 
condition compared to 54.5% in the control condition, OR= 0.66, 95% CI 0.46,0.93) [18].  
 
Given that the current way we communicate side-effect information in PILs in the UK and 
throughout Europe  has been shown to result in people grossly overestimating the risk of 
side-effects [19], positive framing has the potential to be a cost-effective intervention that 
could be easily introduced into PILs in order to rectify this. Future research is needed to test 
this use of positive framing within a clinical population and to assess peoples understanding 
of positively framed side-effect information to see if it leads to more realistic expectations of 
side-effects compared to the current way we communicate. It is also possible interactions 
may exist, for example with people who have higher health literacy being less susceptible to 
positive framing than those with lower health literacy.  
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Regardless, since the UK is now moving into an era where the full presentation of risk 
information is mandatory, it will be important to find ways of doing this without jeopardising 
important therapeutic outcomes. Although this is less of an issue for other countries at this 
time, the use of positively framing side-effect risk should also be considered beyond the UK 
when communication about side-effects is necessary, in order to minimise the risk of nocebo 
effects occurring.  
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